The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TOP: A phase III, multicentre, randomized controlled study comparing osimertinib in combination with carboplatin and pemetrexed to osimertinib monotherapy for untreated patients with advanced non-squamous (Non-sq) non-small cell lung cancer (NSCLC) with concurrent EGFR and TP53 mutations.
 
Yunpeng Yang
No Relationships to Disclose
 
Weineng Feng
No Relationships to Disclose
 
Wei Jiang
No Relationships to Disclose
 
Lu Huang
No Relationships to Disclose
 
Yanqiu Zhao
No Relationships to Disclose
 
Lili Chen
No Relationships to Disclose
 
Yong Fang
No Relationships to Disclose
 
Mei Ji
No Relationships to Disclose
 
Tingting Zhang
No Relationships to Disclose
 
Junfei Zhu
No Relationships to Disclose
 
Li Zhang
No Relationships to Disclose